Basilea Pharmaceutica AG Current Ratio 2010-2021 | BPMUF

Basilea Pharmaceutica AG current ratio from 2010 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Basilea Pharmaceutica AG Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.24B $0.04B 5.84
2020-12-31 $0.24B $0.05B 4.46
2020-06-30 $0.17B $0.04B 4.26
2019-12-31 $0.19B $0.08B 2.45
2018-12-31 $0.28B $0.07B 4.12
2018-06-30 $0.25B $0.06B 3.97
2017-12-31 $0.30B $0.08B 3.69
2017-06-30 $0.24B $0.08B 2.98
2016-12-31 $0.27B $0.07B 3.68
2016-06-30 $0.29B $0.07B 4.42
2015-12-31 $0.40B $0.07B 5.59
2015-06-30 $0.25B $0.07B 3.64
2014-12-31 $0.27B $0.07B 3.97
2014-06-30 $0.29B $0.06B 4.92
2013-12-31 $0.31B $0.07B 4.75
2013-06-30 $0.29B $0.06B 4.99
2012-12-31 $0.38B $0.06B 6.15
2012-06-30 $0.19B $0.03B 5.62
2011-12-31 $0.25B $0.04B 6.45
2011-06-30 $0.30B $0.05B 6.57
2009-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.505B $0.136B
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57